Aromatase inhibitors-where are we now?

Reflection for the undergraduate on writing in the portfolio: where are we now and where are we going?

Introduction: The portfolio can be seen as a tool for assessmentof a variety of learning activities that differ in content, usage, andassessment. The portfolio not only meets the learner’s educationalneeds but also the political and public reassurance demand thatthe health professional has achieved the required competency ofthe curriculum that allows him or her to practice safely with orwithout...

Amyloidosis-where are we now and where are we heading?

CONTEXT Amyloidoses are disorders of diverse etiology in which deposits of abnormally folded proteins share distinctive staining properties and fibrillar ultrastructural appearance. Amyloidosis ultimately leads to destruction of tissues and progressive disease. With recent advances in the treatment of systemic amyloidoses the importance of an early diagnosis of amyloid, and a correct diagnosis ...

Where are we now? Where are we going?

Where are we now and where are we headed?

MMR: where are we now?

T he combined measles, mumps and rubella (MMR) vaccine was introduced to the UK in 1988 and uptake of the vaccine rose rapidly to a high of 92%. In 1992, brands containing the Urabe strain of the mumps vaccine virus were withdrawn after it was noted to be associated with an increased risk of aseptic meningitis. This did not appear to have a deleterious effect on uptake. In 1995, a paper was pub...